For the year ending 2025-12-31, ENSCW made $5,066,650 in revenue. -$10,175,700 in net income. Net profit margin of -200.84%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Federal grants | 5,066,650 | |||
| Research and development | 10,376,895 | |||
| General and administrative | 4,930,701 | |||
| Total operating expenses | 15,307,596 | |||
| Loss from operations | -10,240,946 | |||
| Change in fair value of liability classified warrants | 10,096 | |||
| Interest expense, net | 18,767 | |||
| Other income and expense, net | 73,430 | |||
| Total other income (expense), net | 64,759 | |||
| Net loss | -10,176,187 | |||
| Net loss attributable to noncontrolling interests | -487 | |||
| Net loss attributable to common stockholders | -10,175,700 | |||
| Basic EPS | -3.98 | |||
| Diluted EPS | -3.98 | |||
| Basic Average Shares | 2,557,377 | |||
| Diluted Average Shares | 2,557,377 | |||
Ensysce Biosciences, Inc. (ENSCW)
Ensysce Biosciences, Inc. (ENSCW)